4 Results for "

TG02

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "TG02" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-15166
CAS No.: 937270-47-8
Purity:  99.70%
Synonyms: (E/Z)-TG02; (E/Z)-SB1317
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-15166A
CAS No.: 1321626-25-8
Purity:  99.90%
Synonyms: (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib ((E/Z)-TG02) is an orally active inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-15166B
CAS No.: 1204918-73-9
Purity:  98.06%
Synonyms: (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate
Target:  

CDK JAK FLT3

Research Areas:  

Cancer

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15163
CAS No.: 1204918-72-8
Synonyms: TG02; SB1317
Target:  

JAK CDK FLT3

Research Areas:  

Cancer

Zotiraciclib (TG02; SB1317) is an orally active JAK2/FLT3/CDK2 inhibitor with IC50 values of 13 nM, 73 nM and 56 nM , respectively. Zotiraciclib inhibits cancer cell proliferation, tumor growth and the activity of CYP2D6. Zotiraciclib exhibits high plasma protein binding rate, Caco-2 permeability and tissue distribution capacity, as well as metabolic stability in human and canine liver microsomes. Zotiraciclib achieves tumor growth inhibition in nude mouse models of colon cancer and lymphoma xenografts. Zotiraciclib can be used for research related to colon cancer, B-cell lymphoma, advanced leukemia, acute leukemia and multiple myeloma .
loading...
    loading...